Skip to main content
. 2013 Jun 6;6(2):463–467. doi: 10.3892/ol.2013.1379

Figure 3.

Figure 3.

Post-operative relapse-free survival (RFS) of patients with or without RhoGDI2 mRNA expression in gastric carcinoma. RhoGDI2, Rho GDP dissociation inhibitor 2; N.S, not significant.